Haemonetics Corporation (HAE) : Black Creek Investment Management reduced its stake in Haemonetics Corporation by 18.33% during the most recent quarter end. The investment management company now holds a total of 2,038,681 shares of Haemonetics Corporation which is valued at $73,902,186 after selling 457,610 shares in Haemonetics Corporation , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Haemonetics Corporation makes up approximately 6.39% of Black Creek Investment Management’s portfolio.
Other Hedge Funds, Including , Profund Advisors boosted its stake in HAE in the latest quarter, The investment management firm added 124 additional shares and now holds a total of 13,954 shares of Haemonetics Corporation which is valued at $505,833. Haemonetics Corporation makes up approx 0.02% of Profund Advisors’s portfolio.Alliancebernstein boosted its stake in HAE in the latest quarter, The investment management firm added 5,400 additional shares and now holds a total of 81,390 shares of Haemonetics Corporation which is valued at $2,950,388.California Public Employees Retirement System boosted its stake in HAE in the latest quarter, The investment management firm added 4,200 additional shares and now holds a total of 102,700 shares of Haemonetics Corporation which is valued at $3,518,502. Haemonetics Corporation makes up approx 0.01% of California Public Employees Retirement System’s portfolio.Amg National Trust Bank reduced its stake in HAE by selling 514 shares or 3.2% in the most recent quarter. The Hedge Fund company now holds 15,558 shares of HAE which is valued at $533,017. Haemonetics Corporation makes up approx 0.05% of Amg National Trust Bank’s portfolio.
Haemonetics Corporation opened for trading at $36.32 and hit $36.87 on the upside on Monday, eventually ending the session at $36.84, with a gain of 1.49% or 0.54 points. The heightened volatility saw the trading volume jump to 2,49,561 shares. Company has a market cap of $1,890 M.
On the company’s financial health, Haemonetics Corporation reported $0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 1, 2016. Analyst had a consensus of $0.29. The company had revenue of $210.00 million for the quarter, compared to analysts expectations of $205.41 million. The company’s revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.35 EPS.
Many Wall Street Analysts have commented on Haemonetics Corporation. Haemonetics Corporation was Downgraded by Sidoti to ” Neutral” on Aug 15, 2016. Company shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $32 .Company shares were Reiterated by The Benchmark Company on Aug 2, 2016 to “Hold”, Firm has raised the Price Target to $ 32 from a previous price target of $28 .
Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.